NP与GP方案治疗晚期非小细胞肺癌68例疗效分析  

Vinorelbine plus cisplatin versus gemcitabine plus cisplatin in treatment of patients with advanced non-small cell lung cancer

作　　者：郑玉军[1] 白晓明[1] 杜华昆[1] 

机构地区：[1]大连市中心医院肿瘤科,辽宁大连116033

出　　处：《肿瘤防治杂志》2005年第22期1742-1744,共3页China Journal of Cancer Prevention and Treatment

摘　　要：为了评价NP和GP方案治疗晚期非小细胞肺癌的疗效和不良反应。将1999年12月2日～2004年5月2日收治的68例非小细胞肺癌(nonsmallcelllungcancer,NSCLC)患者随机分为两组,分别应用NP和GP方案治疗。NP方案:长春瑞滨(NVB)25mg/m2,d1、d8;顺铂(DDP)50mg,d3～d5。GP方案:健择(Gemcitabine)1000mg/m2,d1、d8;DDP50mg,d3～d5,两种方案均21d为1个周期,至少治疗2个周期。结果为NP组35例,无CR,PR17例(48.6%),SD13例(37.1%),PD5例(14.3%),总有效率为48.6%(17/35),临床受益率85.7%(30/35)。GP组33例,CR1例(3.0%),PR14例(42.4%),SD13例(39.4%),PD5例(15.2%),总有效率为45.5%(15/33),临床受益率84.8%(28/33)。NP组和GP组中位进展时间分别为3.2和3.3个月,初治优于复治(NP组60%vs33%,GP组52.6%vs35.7%)。剂量限制性毒性主要为骨髓抑制,NP组和GP组白细胞及血小板下降的发生率分别为80%、22.9%和51.5%、51.5%。NP组静脉炎及胃肠道反应较GP组重(31.4%vs6.1%和57.1%vs45.5%)。初步研究结果提示,NP和GP方案治疗晚期NSCLC均安全有效,疗效相当,不良反应均可耐受。The obiective of this study was to compare the efficacy and toxicity of vinorelbine plus cisplatin （NP） and gemcitabine plus cisplatin （GP） combinations in the treatment of advanced non-small cell lung cancer （NSCLC）. From December 1999 to May 2004, a total of 68 patients with advanced NSCLC were randomized to receive vinorelbine 25mg/m^2 on days 1,8 infusion and cisplatin 50mg on days 3,4,5 or gemcitabine 1 000 mg/m^2 on day 1,8 infusion and cisplatin 50mg on days 3,4,5. Both regimens were repeated every 3 weeks. A total of 68 patients （35 patients in group NP, 33 patients in group GP）, were enrolled. The median time to progression was 3. 2 months for group NP and 3.3 months for group GP. The overall response rate for group NP was 48. 6 %, with no complete response （CR）, 48. 6 % of partial response （PR）, 37.1% of stable disease （SD）, 14.3% of progression of disease （PD）, and the benefit rate was 85.7% ,and in group GP, the overall response rate was 45.5% ,with 3. 0% of CR,42. 4% of PR,39.4% of SD, 15.2% of PD,and the benefit rate was 84. 8%. The response rate was higher in previously untreated eases than in treated eases （60% vs 33.3% in group NP, and 52. 6% vs 35.7% in group GP）. The incidences of neutropenia and thrombocytopenia were 80% and 22. 9% in group NP, and 51.5% and 51.5% in group GP, respectively. Phlebitis （31.4% vs 6.1%） and nausea/vomiting （57.1% vs 45.5 % ） were more severe in group NP. In conclusion, both NP and GP combined chemotherapy produce similar efficacy and are well tolerated in patients with advanced non-small cell lung cancer.

关 键 词：癌 非小细胞肺/药物疗法 长春碱 脱氧胞苷 顺铂 抗肿瘤联合化疗方案 

分 类 号：R734.2[医药卫生—肿瘤]